Using nanofibers to target and inhibit metastatic osteosarcoma cells
Testing in-situ formed nanofibers for inhibiting metastatic osteosarcoma (mOS) in murine models
This study is exploring a new way to treat metastatic osteosarcoma by using tiny fibers that can be made inside the cancer cells, and it aims to see if this method can help slow down tumor growth better than current treatments.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brandeis University NIH-funded |
| Lab location | 1 site (Waltham, United States) |
| Project ID | NIH-10448284 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat metastatic osteosarcoma (mOS) by using enzyme-instructed self-assembly (EISA) to form nanofibers within the nuclei of mOS cells. The study aims to synthesize and characterize these molecules and test their effectiveness in inhibiting tumor growth in murine models. By selectively targeting the mOS cells, this method could provide a more effective treatment option compared to existing therapies. The research will involve rigorous testing to ensure the safety and efficacy of these nanofibers in a controlled environment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with metastatic osteosarcoma who may benefit from novel therapeutic approaches.
Not a fit: Patients with non-metastatic osteosarcoma or other types of cancer may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a breakthrough treatment for metastatic osteosarcoma, significantly improving patient outcomes.
How similar studies have performed: While the approach of using nanofibers for targeted cancer treatment is innovative, similar strategies have shown promise in preliminary studies, indicating potential for success.
Where this research is happening
Waltham, United States
- Brandeis University — Waltham, United States (Active)
Researchers
- Principal investigator: Xu, Bing — Brandeis University
- Study coordinator: Xu, Bing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.